TG Therapeutics Inc
Company Profile
Business description
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Contact
3020 Carrington Mill Boulevard
Suite 475
MorrisvilleNC27560
USAT: +1 212 554-4484
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
352
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,571.40 | 40.30 | -0.47% |
CAC 40 | 7,864.44 | 46.05 | -0.58% |
DAX 40 | 23,999.17 | 123.23 | -0.51% |
Dow JONES (US) | 41,859.15 | 1.29 | -0.00% |
FTSE 100 | 8,739.26 | 47.20 | -0.54% |
HKSE | 23,544.31 | 283.47 | -1.19% |
NASDAQ | 18,925.73 | 53.09 | 0.28% |
Nikkei 225 | 36,985.87 | 313.11 | -0.84% |
NZX 50 Index | 12,662.25 | 40.85 | -0.32% |
S&P 500 | 5,842.04 | 2.57 | -0.04% |
S&P/ASX 200 | 8,348.70 | 38.10 | -0.45% |
SSE Composite Index | 3,380.19 | 7.39 | -0.22% |